Abstract
Development of a therapeutic agent is a laborious process commencing with the discovery of a “druggable target” underlying the pathology of a disease. Discovery process is followed by identification of a lead molecule/compound, optimization of the pharmaceutical formulation of the compound, laboratory testing, IND approval, and clinical trials. This article focuses on characterization, pharmaceutical formulation, and clinical studies of bevacizumab (avastin), proteasome inhibitors, interferon-alpha (IFN-•), and oncolytic viruses.
| Original language | English (US) |
|---|---|
| Title of host publication | Pharmaceutical Sciences Encyclopedia |
| Publisher | wiley |
| Pages | 1-39 |
| Number of pages | 39 |
| ISBN (Electronic) | 9780470571224 |
| DOIs | |
| State | Published - Jan 1 2010 |
| Externally published | Yes |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- bevacizumab
- interferon-alpha (IFN-)
- oncolytic viruses
- proteasome inhibitors
ASJC Scopus subject areas
- General Medicine
- General Pharmacology, Toxicology and Pharmaceutics
- General Chemistry
Fingerprint
Dive into the research topics of 'From Concept to the Clinics: Development of Novel Large Molecule Cancer Therapeutics'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS